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4. INTRODUCTION 
4.1 Acute myocardial infarction and ischemia/reperfusion injury 
Ischemic heart diseases are currently the leading causes of morbidity and mortality in 
the world [1]. About 70% of the people with ischemic heart disease die due to an acute 
myocardial infarction [2]. From being an illness seen predominantly in developed countries 
including Hungary, myocardial infarction is now becoming increasingly more common in 
developing countries as well [3]. Myocardial infarction has several risk factors such as 
hyperlipidemia, atherosclerosis, obesity, diabetes mellitus, heart failure, high blood pressure, 
smoking as well as age and gender.  
Myocardial ischemia can be described as an imbalance between oxygen and nutrient 
supply and demand of myocardial tissue. Specifically, myocardial hypertrophy and 
accelerated heart rhythm can enhance oxygen demand, while supply is hampered by partial or 
complete coronary artery occlusion. Coronary occlusion usually is a result of a thrombotic 
event such as rupture of a vulnerable atherosclerotic plaque, formation of a thrombus on the 
erosion of the lesion, or embolization. The definitive therapy for myocardial infarction is still 
the rapid reclamation of blood flow to the ischemic zone of myocardium, as percutaneous 
coronary intervention or if it is not available, thrombolytic therapy. Early reperfusion at least 
partly saves ischemic myocardium; however, reperfusion exacerbates further complications 
such as diminished cardiac contractile function (stunning) and arrhythmias. Therefore the 
prevention of ischemic heart disease is very important to avoid the enormous clinical, 
economic, and social costs of cardiovascular disease. The mechanism, how ischemia damage 
myocardial tissue, is very complex and not exactly known in details. Decreased oxygen and 
nutrient supply cause energy depletion via decreasing the ATP production of the myocardium 
and thus impair transport function (e.g. ouabain-sensitive Na
+
, K
+
-ATPase, SERCA), function 
of protein kinase enzymes, protein synthesis, etc. Under ischemic conditions the decrease in 
pH stimulates Na
+
-H
+
 exchange and Na
+
-HCO3
-
 transporter, which leads to intracellular 
sodium accumulation and development of intracellular Ca
2+
 overload [4] which activates pro-
apoptotic signaling [5]. Energy depletion results opening of the mitochondrial permeability 
transition pore, mitochondrial swelling and apoptosis. Derangement of the mitochondrial 
electron transport system promotes the generation of reactive oxygen species (ROS) and 
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development of oxidative stress in the ischemic heart. ROS react directly with cellular lipids, 
proteins and DNA leading to cell injury/death [6]. ROS are able to influence extracellular 
matrix remodeling through the activation of matrix metalloproteinases (MMPs) [7]. Re-
establishment of adequate oxygen and nutrients can limit the size of the ultimate area of 
infarction. Paradoxically, restoration of normal blood flow to an area of ischemia results in a 
complex cascade of inflammation and further oxidative stress. Ischemia/reperfusion results in 
the loss of contractile function and produces myocardial damage as a consequence of cell 
death from both necrosis and apoptosis [8]. The process involves damage caused by ischemia 
and reperfusion is called ischemia/reperfusion injury. The development of effective 
cardioprotective agents and pretreatments against ischemia/reperfusion injury is of great 
importance and remains a foremost experimental goal of heart research [9].  
4.2 Hypercholesterolemia 
Incidence of metabolic syndrome including obesity, diabetes mellitus, high blood 
pressure, and dyslipidemia is constantly growing worldwide. These diseases especially 
hypercholesterolemia are a well-known risk factor for atherosclerosis and, therefore, coronary 
heart diseases, including myocardial infarction. Hypercholesterolemia usually results from 
nutritional factors such as a diet high in saturated fats, sucrose, and fructose combined with 
decreased physical activity, obesity, and underlying polygenic predispositions [10]. It is well 
known, that hypercholesterolemia increases the incidence of cardiovascular diseases through 
atherosclerosis; however, several studies have shown that hypercholesterolemia exerts direct 
myocardial effects independent of the development of atherosclerosis both in humans [11-13] 
and animal models [14-21]. Different animal models are used to study hypercholesterolemia. 
The human lipid profile and lipid profile of animal models are different and these differences 
allow studying different aspects of hypercholesterolemia. We used the hearts of male Wistar 
rats to study the direct cardiac effects of dietary cholesterol as rats show moderate increase in 
serum cholesterol level due to a high-cholesterol diet without substantial development of 
atherosclerosis [16,22,23]. Hypercholesterolemia independently from the vascular effects 
negatively influences myocardial performance: impairs systolic as well as diastolic contractile 
function [14-16], aggravates the deleterious effects of ischemia/reperfusion injury [17], and 
interferes with the anti-ischemic effect of ischemic pre- [16,18,24] and postconditioning [25] 
(endogenous cardioprotective mechanisms). Furthermore, it has been shown that myocardial 
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function impaired in cholesterol fed rats and this impaired function is in connection with 
increased peroxynitrite level caused by cholesterol [14,20,21]. Cholesterol is the bulk end-
product of the mevalonate pathway [26]. HMG-CoA reductase enzyme is the rate limiting 
step of mevalonate pathway (Figure 1) and therefore, it is highly regulated. The end product 
cholesterol represses the transcription of the HMG-CoA reductase gene [27]. The most 
commonly used cholesterol lowering drugs, statins, are competitive inhibitors of HMG-CoA 
reductase enzyme [28]. In humans a number of large clinical trials have shown that chronic 
administration of statins have potent cholesterol-lowering effects and reduce cardiovascular 
morbidity and mortality [29,30]. On the other hand, it is well known that chronic treatment 
with statins may exhibit a number of extrahepatic adverse effects, such as myopathy and 
rhabdomyolysis [31]. Therefore, it is reasonable to develop new, safer therapeutic tool to 
influence mevalonate pathway. 
4.3 Mevalonate pathway intermediates 
Farnesol (3,7,11-trimethyl-2,6,10-dodecatriene-1-ol), a 15-carbon sesquiterpenoid 
molecule, increases the degradation of HMG-CoA reductase enzyme [32]. Bentinger et al. 
(1998) has shown in rats that farnesol could be phosphorylated in vivo to form farnesyl-
pyrophosphate [33] which is a key branching point in the mevalonate pathway [26] (Figure 1) 
and, therefore, farnesol is able to modulate the mevalonate pathway [34]. We have previously 
shown that administration of farnesol restored the protective effect of preconditioning in 
cholesterol fed rats [9,35]; however, it is not known if farnesol itself is able to protect the 
heart against ischemia/reperfusion injury. Farnesol is naturally occurring mainly in aromatic 
fruits [36] and is known as a powerful antioxidant [36-38]. Farnesyl-pyrophosphate can be 
further metabolized to the mevalonate pathway end-products i.e. cholesterol, coenzyme Q, 
and dolichol [26]. Moreover, farnesyl-pyrophosphate is a precursor for the prenylation 
(farnesylation and/or geranylgeranylation) of several intracellular proteins. Protein 
prenylation is a common post-translational modification of several intracellular proteins 
[26,39] (Figure 1) and prerequisite for their physiological function. Examples of prenylated 
proteins include the γ subunit of heterotrimeric G-proteins, nuclear lamins, and some 
members of the Ras superfamily of small GTPases e.g.: Ras, Rho, Rac, Rab subfamily [40-
42]. Although several G-proteins are involved in the signal-transduction of 
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ischemia/reperfusion injury and cardioprotection, the role of their prenylation has not been 
investigated in ischemia/reperfusion injury. 
Farnesyl pyrophosphate is also a precursor for the synthesis of different forms of 
coenzyme Q such as coenzyme Q10 that is most common coenzyme Q in humans and 
coenzyme Q9 that is most common in rats [43] (Figure 1). Coenzyme Q plays a major role in 
the mitochondrial electron-transport chain and serves as an endogenous antioxidant [43]. 
Coenzyme Q is protective against myocardial ischemia/reperfusion-injury in animal studies 
[44,45] and it is a registered drug for adjuvant therapy of heart failure worldwide. 
 
Figure 1. The mevalonate pathway. 
Dolichol, another derivative of farnesyl pyrophosphate (Figure 1), is the most 
prevalent polyisoprenyl glycosyl carrier in eukaryotes involved in C- [46] and O-
mannosylaton of proteins, the formation of glycosylphosphatidylinositol anchors [47] and the 
N-glycosylation of proteins [48]. The role of dolichol in ischemia/reperfusion is not known. 
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Farnesol has been shown to exert an antioxidant effect in-vivo [36-38] and to restore 
reduced glutathione, glutathione reductase and glutathione peroxidase levels [36-38]. The 
above findings may support the potential cardioprotective effect of farnesol, since reactive 
oxygen and nitrogen species e.g. peroxynitrite formed nonenzymatically from NO and 
superoxide, play a pivotal role in ischemia/reperfusion injury [49,50]. 
4.4 Red palm oil 
Red palm oil (RPO) is a natural oil obtained from oil palm fruit (Elaeis guineensis). 
RPO is an antioxidant rich oil which contains approximately 50% saturated and 50% 
unsaturated fatty acids [51,52]. Carotenoids and vitamin E (75% of which is tocotrienol) are 
the most abundant antioxidants in this oil. Both of these antioxidants are contained at a level 
of at least 500 ppm in RPO [51,52]. The cocktail of antioxidants within RPO is believed to 
have synergistic effects [53,54]. The oil offers cardioprotection, by activation of several 
different protective pathways which work synergistically together [55]. Dietary RPO 
supplementation has previously been shown to offer protection against ischemia/reperfusion 
injury in the isolated perfused heart [56-58]. Esterhuyse and co-workers (2005) [56] showed 
that dietary RPO supplementation could improve post ischemic functional recovery in rats fed 
a standard rat chow diet (SRC), and rats fed a SRC plus 2% cholesterol for six weeks [56]. 
They suggested that RPO mediated protection against ischemia/reperfusion injury may be 
induced through different pathways in hearts of SRC fed and cholesterol fed rats. 
4.5 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a large family of zinc dependent 
endopeptidases that recognized for their ability to remodel the extracellular matrix [59]. 
MMPs involved in remodeling the extracellular matrix during various physiological functions 
such as embryonic development, angiogenesis, morphogenesis, wound healing, tissue repair 
and play a role in several pathological conditions such as cancer, cardiovascular disease, 
arthritis, inflammation, diabetes, etc. [19,60]. There are evidences that in pathological 
condition MMPs are able to proteolytically cleave intracellular proteins [61]. MMPs are 
synthesized in a latent form (zymogen or pro-MMP), and are activated by proteolytic 
cleavage of an amino terminal domain or by conformational changes induced by denaturing 
agents or oxidative stress molecules such as peroxynitrite. Normally MMPs are activated by 
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removal of the autoinhibitory propeptide domain by proteases resulting in an active truncated 
MMP. Recently it was found that MMP2 plays a role in ischemia/reperfusion damage in the 
heart [62] as ischemia induced activation and release of MMP-2 is a major effector of acute 
mechanical dysfunction after ischemia/reperfusion in rat hearts [62-64]. Increased MMP2 
activity has also been associated with hypercholesterolemic diets [9]. This may be due to the 
increased peroxynitrite production within the myocardium [14]. ROS and peroxynitrite have 
been shown to activate MMP2 through redox modification of the regulatory site of this 
enzyme [19,65-68]. This redox modification leads to activity being displayed in the 75 and 72 
kDa isoforms of the enzyme, while only the 64 kDa isoform is active if MMP2 is activated in 
the classical manner [19,66]. Activated MMP2 damages cardiomyocytes during reperfusion. 
This is achieved by cleaving the contractile protein regulatory element, troponin I and 
possibly other structural and cytoskeletal proteins [61,69-73]. Activation of MMP2 during an 
ischemic insult is therefore, normally associated with decreased functional recovery and 
larger infarct size of the heart [62,74-77]. This has been confirmed through inhibition of 
MMP2 by antibodies or chemical agents [78-82]. The RPO has antioxidant properties and 
therefore, may inhibit the peroxynitrite induced activation of MMP2. 
In a recent study [83] it was shown that red palm oil reduced infarct size in a model of 
ischemia/reperfusion injury. However, this model investigated only hearts of healthy animals. 
The intention of the current study was therefore, to use a high cholesterol feeding model to 
ensure that the model is more clinically relevant and to establish confirmation that red palm 
oil protection are indeed applicable in unhealthy diets, as was previously argued. In all red 
palm oil fed studies up to date [55-58], results have indicated post-ischemic involvement of 
certain cellular biochemical pathways. However, none of these studies provided any evidence 
of pre-ischemic protection by red palm oil. Mechanism of RPO induced protection is not 
known; however, we hypothesized that RPO may attenuate peroxynitrite induced MMP 
activation.  
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5. Aims 
The aims of this study were: 1) to investigate the cardioprotective effect of farnesol 
and 2) to determine whether the antioxidant effect of farnesol or the increased coenzyme Q, 
protein prenylation and dolichol formation may protect myocardium against 
ischemia/reperfusion injury. Furthermore, our aims were 3) to investigate the effects of 
dietary RPO supplementation on myocardial infarct size in the hearts of rats on a cholesterol 
enriched diet and 4) to determine whether MMP2 activity was altered by RPO 
supplementation, both pre- and postischemically. 
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6. MATERIALS AND METHODS 
This investigation conformed to the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and was approved by 
the local ethics committee at the University of Szeged. 
6.1. Experimental design and isolated heart perfusion protocol of study 1 
Here we assessed the effect of subchronic farnesol treatment on ischemic tolerance 
and biochemical changes of the heart. 
Male Wistar rats (300-400 g, n=108 in the entire study 1) were kept under controlled 
temperature with 12/12h light/dark cycles. They received a standard rodent chow and tap 
water ad libitum. Rats were randomly assigned to the following groups: oral administration of 
vehicle (2.5% methylcellulose) or 0.2, 1, 5, and 50 mg/kg/day farnesol (SAFC Supply 
Solution, St Louis, MO), respectively for 12 days. The length of farnesol administration and 
doses were applied according to previous studies [36,84].  
On day 13, the effect of farnesol on cardiac ischemic tolerance and biochemical 
changes was tested. Therefore, rats were anesthetized, heparin (500 U/kg iv) was 
administered, and hearts were isolated and perfused at 37°C in Langendorff mode with 
oxygenated Krebs-Henseleit buffer with constant pressure as previously described [35,84]. 
Hearts were subjected either to (i) 30 min coronary occlusion followed by 120 min 
reperfusion to measure infarct size in all groups (n=12-14 except for the 0.2 mg/kg/day 
farnesol treated group where n=8) or to (ii) 10 min of perfusion to wash out blood before 
tissue sampling for biochemical assays from selected groups as appropriate (see results). 
Cardiac levels of mevalonate pathway end-products (prenylated proteins, cholesterol, 
coenzyme Q9, Q10, and dolichol; n=13 in the vehicle and the 1 mg/kg/day farnesol treated 
group), and 3-nitrotyrosine (marker of oxidative/nitrosative stress, n=7 in the vehicle and the 
1 and 50 mg/kg/day farnesol treated group) were measured from the tissue samples in 
separate experiments, respectively (Figure 2). Background morphological and 
hemodynamical parameters such as body weight, heart weight, and coronary flow before 
ischemia were measured from all animals served for infarct size measurement and assessment 
of biochemical parameters (Table 1).  
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Figure 2. Experimental protocol of study 1. Male Wistar rats were treated with vehicle 
(2.5% methylcellulose) or 0.2, 1, 5, and 50 mg/kg/day farnesol, respectively for 12 days 
per os by gavage. On day 13, hearts were isolated to test the effect of the different 
treatments on cardiac ischemic tolerance and biochemical changes. To test ischemic 
tolerance, hearts from all groups were subjected to 30 min coronary occlusion followed 
by 120 min reperfusion to measure infarct size. To measure changes in cardiac 
biochemical parameters from selected groups, hearts were subjected to 10 min of 
aerobic perfusion to wash out blood before tissue sampling. 
6.2. Experimental design and isolated heart perfusion protocol of study 2 
Male Wistar rats were divided into four groups. Rats in these groups were placed on 
the following diets, respectively: 
Group 1: Standard rat chow diet for 9 weeks (Norm) 
Group 2: 2% cholesterol-enriched diet for 9 weeks (Chol) 
Group 3: Standard rat chow supplemented with 200 μl RPO (Norm+RPO) per day for 
the last 5 weeks of the 9 week period 
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Group 4: 2% cholesterol-enriched diet for nine weeks supplemented with 200 μl RPO 
per day for the last 5 weeks of the 9 week period (Chol+RPO) 
Rats were individually housed to ensure that each animal received equal amounts of 
supplements. RPO and supplements were prepared on a daily basis in order to prevent 
spoiling. The red palm oil doses were applied according to previous studies [85]. Rats were 
allowed ad libitum access to food and water. 
 
Figure 3. Experimental protocol of study 2. Male Wistar rats were fed with standard rat 
chow or 2% cholesterol supplemented rat chow for 9 weeks with or without red palm oil 
supplementation in the last 5 weeks. To assess ischemic tolerance hearts were subjected 
to 30 min global ischemia followed by 120 min reperfusion. Serum samples were taken 
from rats before perfusion protocol to assess serum cholesterol and serum triglyceride 
levels. Coronary effluents were collected before and after ischemia to assess cardiac 
MMP2 activity. 
After the feeding period, rats were anaesthetized using diethyl ether. Hearts were 
isolated, mounted on a Langendorff perfusion apparatus, and were perfused at 37°C using a 
Krebs-Henseleit buffer solution which was constantly gassed with 5% carbon dioxide, 95% 
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oxygen and a constant perfusion pressure of 100 cmH20 was maintained. After mounting, 
hearts were subjected to 10 minutes of stabilization, followed by 30 minutes of normothermic 
global ischemia and 120 minutes of reperfusion. At the end of the perfusion protocol infarct 
size was measured. 
6.3. Infarct size determination 
To assess ischemic tolerance of the heart, infarct size was measured as follows. In case 
of coronary occlusion (study 1) at the end of the perfusion protocol, the coronary artery was 
reoccluded and 5 ml of 0.1% Evans blue dye was injected into the aorta to delineate the area 
at risk zone and after that the hearts were frozen. In case of global ischemia (study 2) the 
hearts were frozen without Evans blue dying. Frozen hearts were then sliced, and incubated 
for 10 min at 37°C in 1% triphenyltetrazolium chloride to delineate infarcted tissue. Slices 
were then fixed in formalin solution 10 min at 37°C and then placed in phosphate buffer (pH 
7.4) [84,86]. Heart slices were then placed between two sheets of glass and scanned into a 
computer and analyzed using infarct size planimetry software (Infarctsize™ 2.4 
Pharmahungary, Szeged, Hungary) in a blinded manner. Infarct size was expressed as a 
percentage of the area at risk. In case of coronary occlusion (study 1) the area at risk was 
calculated as a percentage of the total ventricular area [84,86]. In case of global ischemia 
(study 2) the area at risk was the total ventricular area [84,86]. 
6.4. Measurement of myocardial protein geranylgeranylation and farnesylation 
The nucleophilic cleavage of the allylic thiol bond by 2-naphthol provides for 
quantitative determination of the cysteine-bound prenyl groups of prenylated proteins. The 
level of cysteine-bound farnesyl and geranylgeranyl groups were measured by HPLC method 
as previously described [87]. Briefly, 200 mg tissue samples were delipidated by extraction 
with ethanol followed by diethyl ether. Delipidated samples were mixed with 2.5 ml reagent 
mixture (20 mg/mL potassium naphthoxide dissolved in dioxane). Then dioxane was removed 
with a stream of nitrogen gas and 100 µl dimethylformamide was added to the samples and 
were heated at 100°C for 8 hours. The reaction products were extracted with 400 µl n-hexane 
and the upper phase was injected to YL9100 HPLC system on a YMC-Pack ODS-A 250 
mm×4.6 mm ID 5 μm using 95-100% acetonitrile as mobile phase. Calibration curves were 
made using N-acetyl-S-farnesyl-L-cysteine and N-acetyl-S-geranylgeranyl-L-cysteine 
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standards (Sigma, St. Louis, MO) underwent the same preparation procedure. Therefore, 
protein farnesylation and geranylgeranylation were expressed as protein-bound farnesyl and 
geranylgeranyl group in ng/mg protein. 
6.5. Measurement of myocardial cholesterol 
Tissue cholesterol was measured (Cholesterol/Cholesterol Ester Quantification kit; 
BioVision, Mountain View, CA) from ventricular homogenates according to the 
manufacturer’s instructions. Ten mg ventricular homogenates were used for tissue cholesterol 
measurement. Myocardial cholesterol was expressed in ng/mg protein. 
6.6. Measurement of myocardial coenzyme Q 
The level of cardiac coenzyme Q9 and Q10 were measured by a HPLC method 
following lipid extraction with n-hexane as previously described [88]. Coenzyme Q9 and Q10 
were detected at 275 nm using an YL 9160 PDA detector following separation with a YL9100 
HPLC system on a C18 column (YMC Basic, 50 mm×4.6 mm ID 3 μm). Four hundred mg 
ventricular homogenate was used for myocardial coenzyme Q measurement. Calibration 
curves were made using coenzyme Q9 and Q10 standards (Sigma, St. Louis, MO). 
Myocardial coenzyme Q9 and Q10 were expressed in ng/mg protein. 
6.7. Measurement of myocardial dolichol 
The level of cardiac dolichol was measured by HPLC method as previously described 
[89]. Briefly, minced cardiac tissues (400 mg) were mixed with 0.5 ml 0.25% pyrogallol in 
methanol and 0.5 ml 60% KOH. Hydrolysis was performed in a water bath at 100°C for 30 
min; the mixture was extracted three times with diethyl ether:petroleum ether (1:1). The 
pooled extracts were washed with methanol:diethyl ether (1:1) and were dried under nitrogen. 
The samples were resolved with isopropanol:acetonitrile (65:35). Dolichol was detected at 
210 nm using an YL 9160 PDA detector following separation with an YL9100 HPLC system 
on C18 column (YMC-Pack ODS-AQ, 10 mm×4.0 mm ID 3 µm and YMC-Pack ODS-AQ, 
150 mm×4.6 mm ID 5 µm). Calibration curve was made using C90-Dolichol standard 
(Larodan, Malmö, Sweden). Myocardial dolichol was expressed in ng/mg protein. 
6.8. Measurement of 3-nitrotyrosine 
Cardiac free 3-nitrotyrosine content, as markers for peroxynitrite-induced 
oxidative/nitrosative stress, was measured after 10 minutes of perfusion. Cardiac free 3-
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nitrotyrosine level was measured by enzyme-linked immunosorbent assay (ELISA; Cayman 
Chemical, Ann Arbor, MI) from heart tissue samples according to the instructions. Briefly, 
supernatants of 50 mg ventricular tissue homogenate was incubated overnight with anti-
nitrotyrosine rabbit IgG specific to free 3-nitrotyrosine and nitrotyrosine acetylcholinesterase 
tracer in precoated (mouse anti-rabbit IgG) microplates followed by development with 
Ellman’s reagent. Free 3-nitrotyrosine content was normalized to protein content of cardiac 
homogenate and expressed as ng/mg protein. 
6.9. Measurement of protein concentration 
Protein concentrations were measured by the BCA Protein Assay kit (Thermo, 
Rockford, IL) according to the instructions. 
6.10. Neonatal cardiomyocyte culture experiments 
In order to investigate if farnesol has a direct cardiocytoprotective effect, we 
investigated whether farnesol protects cardiomyocytes subjected to simulated 
ischemia/reperfusion. Neonatal cardiomyocyte cultures were prepared as described previously 
[90]. Cells were kept in normoxic incubator and supplied with proliferation medium for 1 day 
(DMEM + 10% FBS). Then farnesol (0.0032 – 250 µM) was administered in differentiation 
medium (DMEM + 1% FBS) for 2 days. After farnesol treatment, the culture medium was 
changed to hypoxic solution [91] and plates were placed into a hypoxic chamber, and cells 
were exposed to a constant flow of a mixture of 95% N2 and 5% CO2 at 37 °C for 4 h. 
Simulated ischemia was followed by 2 h simulated reperfusion using differentiation medium 
and normoxia (Figure 4). To assess cell viability cardiomyocytes were incubated with 1 µM 
calcein acetoxymethyl ester (calcein-AM, Sigma, St Louis, MO) at room temperature for 30 
min. Fluorescence intensity was measured with a fluorescence plate reader (Fluostar Optima, 
BMG Labtech, Ortenberg, Germany) at 490-nm excitation and 520-nm emission filters. 
Simulated ischemia/reperfusion resulted in 21% decrease in cell viability as compared to 
normoxia (4 h normoxia with normoxic solution followed by simulated reperfusion, data not 
shown). 
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Figure 4. Experimental protocol of cardiomyocyte culture experiments. To assess the 
protective effect of farnesol, neonatal rat cardiomyocytes were treated with 0.0032, 
0.016, 0.08, 0.4, 2, 10, 50, and 250 µM farnesol or its vehicle (0.1% DMSO), respectively. 
To test ischemic tolerance, cardiomyocytes were subjected 4 h simulated ischemia and 2 
h simulated reperfusion. Cell viability was assessed by calcein viability assay. 
6.11. MMP2 zymography 
Coronary effluent collected for 10 minutes before ischemia and the first 10 minutes of 
reperfusion was concentrated by ultra-filtration using Amicon ultra filtration tubes (Millipore, 
Billerica, MA). The concentrated coronary flow was then subjected to gelatin zymography. 
Gelatinolytic activities of MMPs were examined as previously described [19]. Briefly, 
polyacrylamide gels were copolymerized with gelatin, and a constant amount of protein was 
separated by electrophoresis in each lane. Following electrophoresis, gels were washed with 
2.5% Triton X-100 and incubated for 20 hours at 37°C in incubation buffer. Gels were then 
stained with 0.05% Coomassie Brilliant Blue in a mixture of methanol/acetic acid/water and 
destained in aqueous 4% methanol/8% acetic acid. Zymograms were digitally scanned, and 
band intensities were quantified using Quantity One software (Bio-Rad, Hercules, CA) and 
expressed as a ratio to the internal standard. 
6.12. Serum cholesterol and triglyceride measurement 
Serum cholesterol and triglyceride were measured using a test kit supplied by 
Diagnosticum Zrt. (Budapest, Hungary) as described previously [20]. 
6.11. Statistics 
All values are presented as mean±SEM. Differences among means were analyzed by 
Student’s unpaired t-test or one-way ANOVA followed by an appropriate post hoc test, 
respectively. All comparisons were made versus the vehicle-treated or vehicle-treated 
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ischemia/reperfusion group or corresponding control group. Statistical significance was 
defined as p<0.05. 
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7. RESULTS 
7.1 Study 1 
7.1.1 Infarct size 
To assess the cardioprotective effect of different oral doses of farnesol, infarct size 
was measured after 30 min regional ischemia and 120 min of reperfusion. Infarct size was 
significantly decreased by 1 mg/kg/day farnesol (22.3±3.9% vs. 40.9±6.1%, p<0.05, Figure 
5). However, 0.2, 5, and 50 mg/kg/day farnesol treatment did not significantly decrease 
infarct size (37.3±5.1%, 32.0±3.1%, 43.5±5.1% vs. 40.9±6.1%, respectively, Figure 5). 
Therefore, the infarct size reducing effect of farnesol showed a U-shaped dose-response 
relationship. Farnesol did not affect body weight, heart weight, coronary flow and heart rate 
(Table 1). 
 
Figure 5. Effect of farnesol on myocardial infarct size. Infarct size is expressed as a 
percentage of the area at risk of isolated hearts that was subjected to 12 days vehicle or 
0.2, 1, 5, and 50 mg/kg/day farnesol treatment followed by 30 min coronary occlusion 
followed by 120 min reperfusion to measure infarct size. Values are mean±SEM; n = 8–
13 in each group; *p < 0.05 vs. vehicle. 
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Farnesol (mg) vehicle 0.2 1 5 50 
Body weight (g) 350 ±5(34) 337 ±8(8) 353 ±5(32) 334 ±3(14) 361 ±6(20) 
Heart weight (g) 1.28 ±0.02(34) 1.27 ±0.06(8) 1.30 ±0.03(32) 1.21 ±0.04(14) 1.27 ±0.04(20) 
Area at risk (%) 54.9 ±3.2(10) 43.7 ±4.4(8) 46.2 ±4.6(11) 64.9 ±3.6(12) 50.1 ±2.6(13) 
Coronary flow (mL/min) 
Before isch 17.9 ±0.5(33) 17.2 ±1.6(8) 18.0 ±0.6(32) 16.6 ±0.7(14) 16.9 ±1.1(18) 
During isch 10.1 ±1.1(11) 9.3 ±1.0(8) 9.8 ±0.5(12) 10.1 ±0.8(12) 9.0 ±0.7(13) 
0-5 min of rep 88.0 ±6.2(11) 72.6 ±5.3(8) 82.8 ±6.6(12) 88.0 ±7.7(12) 75.1 ±4.0(13) 
End of rep 12.6 ±1.3(11) 11.5 ±1.4(8) 14.4 ±1.1(12) 14.3 ±1.5(12) 11.6 ±0.8(13) 
Heart rate (beats/min) 
Before isch 284 ±18(14) 270 ±24(8) 284 ±17(12) 277 ±24(13) 303 ±9(13) 
End of isch 250 ±27(7) 275 ±35(8) 288 ±28(11) 292 ±31(11) 308 ±19(7) 
End of rep 288 ±9(6) 279 ±23(7) 239 ±28(8) 259 ±35(8) 294 ±17(8) 
Table 1. Body weight, animal weight, area at risk and cardiac functional parameters in 
vehicle or 0.2, 1, 5, and 50 mg/kg/day farnesol-treated groups for 12 days followed by 
either 10 min of aerobic perfusion for tissue sampling or 30 min coronary occlusion 
followed by 120 min reperfusion to measure infarct size. Body weight, heart weight, and 
coronary flow before ischemia were measured from all animals served for infarct size 
measurement and assessment of biochemical parameters to yield sample size n=6-34 in 
different groups. Values are mean±SEM (n). 
7.1.2 Mevalonate pathway end-products 
In separate sets of experiments, to assess the effect of cardioprotective (1 mg/kg/day) 
dose of farnesol on mevalonate pathway end-products, we measured cardiac protein 
prenylation, cholesterol, coenzyme Q, and dolichol. We found that oral farnesol treatment 
significantly increased cardiac protein-bound geranylgeranyl level (8.4±0.9 vs. 5.5±0.8 
ng/mg protein, p<0.05) (Figure 6). However, farnesol did not influence cardiac protein-bound 
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farnesyl level (1.6±0.2 vs. 2.7±0.5 ng/mg protein), cardiac cholesterol (100.4±4.5 vs. 
88.8±7.8 ng/mg protein), coenzyme Q9 and Q10 (13.1±0.7 vs. 11.0±2.8 ng/mg protein and 
0.89±0.06 vs. 0.74±0.19 ng/mg protein, respectively), and dolichol levels significantly 
(0.32±0.03 vs. 0.37±0.03 ng/mg protein) (Figure 6).  
 
Figure 6. Cardiac mevalonate pathway metabolites (cardiac cholesterol, coenzyme Q10, 
protein geranylgeranylation, protein farnesylation, coenzyme Q9, and dolichol) from 
rats orally treated with vehicle or 0.2, 1, 5, and 50 mg/kg/day farnesol for 12 days. 
Values are mean±SEM; n = 6–8 in each group. *p < 0.05 vs. vehicle. 
7.1.3 3-nitrotyrosine 
To assess the antioxidant effect of the cardioprotective dose of farnesol in the heart, in 
separate experiments, we measured cardiac 3-nitrotyrosine level as marker of cardiac 
peroxynitrite which is a major player in cardiac oxidative and nitrosative stress. We found that 
the cardioprotective dose of farnesol (1 mg/kg/day) did not affect cardiac 3-nitrotyrosine level 
(Figure 7). Therefore, to further assess if farnesol at a higher dose may show an antioxidant 
effect, in separate experiment, we measured 3-nitrotyrosine in the 50 mg/kg/day
 
farnesol-
treated group. This dose of farnesol (50 mg/kg/day) significantly decreased cardiac 3-
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nitrotyrosine level (1.2±0.2 vs. 2.4±0.5 ng/mg protein, p<0.05) (Figure 7), however, it did not 
show any cardioprotective effect (see above, Figure 5). 
 
Figure 7. Cardiac 3-nitrotyrosine from rats oral treated with vehicle or 1 and 50 
mg/kg/day farnesol for 12 days. Values are mean±SEM; n = 7 in each group, *p < 0.05 
vs. vehicle. 
7.1.4 Cardiomyocyte culture results 
To assess if farnesol has a direct cardiocytoprotective effect, we measured cell 
viability of cardiomyocytes subjected to simulated ischemia/reperfusion. Farnesol (0.0032 – 
50 µM) protected cardiomyocytes in a bell-shaped concentration-response manner similarly to 
that observed in the isolated heart experiments (0.016 µM farnesol: 40.4±1.4 AU, 0.08 µM 
farnesol: 39.6±1.5 AU, 0.4 µM farnesol: 43.1±1.0 AU vs. 34.8±1.2 AU, respectively, Figure 
8). However, 250 µM farnesol showed a cytotoxic effect (data not shown).  
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Figure 8. Viability assay for neonatal rat cardiomyocytes treated with 0.0032, 0.016, 
0.08, 0.4, 2, 10, and 50 µM farnesol or its vehicle (0.1% DMSO), respectively for 2 days. 
Values are mean±SEM; n = 16-24 well. *p < 0.05 vs. vehicle. 
7.2 Study 2 
7.2.1 Animal mass 
The body and heart weight of the RPO supplemented rats were significantly decreased 
when compared to the Norm group and also to the Chol+RPO group after the feeding period 
(Table 2). 
 Norm Chol Norm+RPO Chol+RPO 
Animal mass (g) 494.0±18.1 472.6±13.5 381.3± 7.6* 511.5±14.4 
Heart mass (g) 1.6±0.1 1.7±0.1 1.4±0.1* 1.7±0.1 
Table 2. Animal mass and heart mass after a nine week diet. Values are mean ± SEM, n 
= 8; *p < 0.05 versus Norm and Chol+RPO. 
28 
7.2.2 Perfusion data 
There were no significant differences in the coronary effluent of any of the groups 
after the supplementation period. Coronary effluent of all groups except the RPO group was 
significantly decreased after ischemia, when compared to their baseline values. There were no 
significant differences in the heart rates before or after ischemia (Table 3). 
 
CE before 
ischemia 
(mL/10min) 
CE after 
ischemia 
(mL/10min) 
HR before 
ischemia 
(BPM) 
HR after 
ischemia 
(BPM) 
Norm 205.0±5.7 59.2±4.0* 387.4±56.5 338.0±128.6 
Chol 185.9±21.7 67.1±6.5* 390.8±37.3 346.0±115.3 
Norm+RPO 152.5±12.9 100.0±6.9 344.1±12.0 328.0±40.7 
Chol+RPO 141.9±12.5 61.9±3.8* 327.3±17.6 339.0±29.2 
Table 3. Coronary effluent (CE) collected for 10 min to measure MMP activity and 
heart rate (HR) before and after ischemia. Values are mean ± SEM, n = 8; *p < 0.05 
versus the corresponding “before ischemia” values. 
7.2.3 Infarct size 
Cholesterol-enriched diet alone increased myocardial infarct size from 23.5 ± 3.0% to 
37.2 ± 3.6% (p < 0.05) when compared to normal diet. RPO supplementation significantly 
reduced infarct size in Norm+RPO and also in Chol+RPO (9.2 ± 1.0% and 26.9 ± 3.0%), 
respectively (Figure 9). Infarct size in Chol+RPO group was comparable to the group fed with 
normal diet. 
7.2.4 MMP2 
Before ischemia activity of the 75kDa isoform of MMP2 was significantly lower in 
the Chol+RPO group when compared to the Chol group (228 ± 28 AU versus 450 ± 34 AU; 
(Figure 10). After ischemia MMP2 (72kDa isoform) activity of the RPO supplemented group 
was significantly increased when compared to rats with normal diet (2472 ± 132 AU versus 
2007 ± 68 AU; Figure 11). 
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Figure 9. Myocardial infarct size in rats fed different diets for nine weeks. Infarct size is 
expressed as a percentage of the area at risk, values are mean ± SEM, n = 8; *p < 0.05 
versus corresponding non-RPO treated groups; #p < 0.05 versus corresponding normal 
diet. 
7.2.5 Serum lipid profile 
There were no significant differences in the serum total cholesterol and triglyceride 
level among groups (Table 4). 
 Norm Chol Norm+RPO Chol+RPO 
Total cholesterol 
(mmol/L) 
 
1.96±0.05 
 
1.91±0.05 2.15±0.23  1.79±0.04 
Triglycerides 
(mmol/L) 
0.72±0.06 0.80±0.08 0.71±0.06 0.80±0.07 
Table 4. Serum total cholesterol and serum triglyceride levels of rats after nine weeks of 
diet. Values are mean ± SEM, n = 8. 
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Figure 10. MMP2 activity in coronary effluent collected for 10 minutes before ischemia. 
Values are mean ± SEM, n = 8; *p <0.05 versus corresponding non-RPO treated groups; 
#p < 0.05 versus corresponding normal diet. 
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Figure 11. MMP2 activity in coronary effluent collected for the first 10 minutes of 
reperfusion. Values are mean ± SEM, n = 8; *p < 0.05 versus corresponding non-RPO 
treated groups; #p < 0.05 versus corresponding normal diet. 
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8 DISCUSSION 
8.1 Study 1 
This is the first demonstration that oral farnesol treatment reduces infarct size in the 
rat heart following ischemia/reperfusion. We also found that farnesol shows a direct 
cytoprotective effect in cardiomyocytes subjected to simulated ischemia/reperfusion. 
Furthermore, we found that the in-vivo cardioprotective dose of farnesol (1 mg/kg/day for 12 
days) increased the geranylgeranylation of cardiac proteins, however, it did not affect other 
mevalonate pathway-derived end-products (cardiac cholesterol, coenzyme Q, dolichol) and 
cardiac peroxynitrite marker 3-nitrotyrosine level significantly. This shows that the 
cardioprotective effect of farnesol is independent of its antioxidant effect but may involve 
changes in protein geranylgeranylation (Figure 12). 
 
Figure 12. Proposed mechanism of cardioprotection by farnesol. 
It is known that mammalian cells can utilize farnesol for protein prenylation [34] and 
for synthesis of other mevalonate pathway derivatives (cholesterol, coenzyme Q, and 
dolichol) [34] (Figure 1). Bentinger et al. (1998) has shown in rats that farnesol could be 
phosphorylated in vivo to form farnesyl-pyrophosphate, which could re-enter biosynthetic 
reactions [33]. Our present results support this finding since administration of exogenous 
farnesol increased total myocardial protein geranylgeranylation and reduced infarct size. 
Prenylation (protein farnesylation and geranylgeranylation) is a lipid post-translational 
modification of proteins involving the irreversible covalent attachment of either farnesyl (15-
carbon) or geranylgeranyl (20-carbon) isoprenoid to conserved cysteine residues at or near the 
C-terminus of numerous cellular proteins [92]. Prenyl groups act as hydrophobic membrane 
anchors [40] and play key role in the maturation of proteins [41], regulation of protein 
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targeting, function of proteins, and controlling apoptosis [40,93]. Large number of proteins is 
known to be prenylated, such as e.g. γ subunit of heterotrimeric G-proteins, nuclear lamins, 
and some members of the Ras superfamily of small GTPases e.g.: Ras, Rho, Rac, Rab 
subfamily [40-42]. Some of these proteins have been shown to be involved in 
cardioprotection. Brar et al. (2004) also showed that cardioprotective effect of urocortin-II 
against ischemia/reperfusion injury in rat heart was completely abolished by the Ras inhibitor 
manumycin A [94]. It was also shown that infarct size was increased in cardiac specific RhoA 
knockout mice hearts and was significantly decreased in cardiac-specific RhoA transgenic 
mice [95]. It was also reported that activation of c-Jun N-terminal kinase through the 
Rac1/cdc42-TAK-1 pathway promotes survival of cardiac myocytes after hypoxia-
reoxygenation [96]. Members of the Rab subfamily are geranylgeranylated [40] while the 
other small GTPases either farnesylated or geranylgeranylated [93]. In our present study, we 
measured total protein farnesylation and geranylgeranylation and found that farnesol 
treatment significantly increased total myocardial protein geranylgeranylation but not 
farnesylation. However, the reason for the discrepancy between farnesol-induced protein 
geranylgeranylation and farnesylation remained unknown and it was not investigated in our 
present study. Protein prenylation is catalysed by prenyl transferase enzymes, which can be 
classified into two main functional classes: (i) the CAAX prenyl transferases including 
farnesyl transferase and geranylgeranyl transferase type 1, [93], and (ii) the Rab 
geranylgeranyl transferase (geranylgeranyl transferase type 2) [40]. CAAX prenyltransferase 
activities are highly selective for their isoprenoid diphosphate substrates: farnesyl transferase 
for farnesyl-pyrophosphate and geranylgeranyl transferase type 1 for geranylgeranyl-
pyrophosphate. However, farnesyl transferase can also bind geranylgeranyl-pyrophosphate 
with low affinity, yet the enzyme is unable to transfer the geranylgeranyl group to substrate 
proteins, indicating that geranylgeranyl-pyrophosphate is a competitive inhibitor of farnesyl 
transferase [93]. This might explain our findings regarding the difference between farnesol-
induced protein geranylgeranylation and farnesylation.  
Farnesyl-pyrophosphate can be utilized for synthesis of cholesterol, coenzyme Q, and 
dolichol [26]. In our present study, we have observed that cardiac tissue cholesterol content 
expressed in ng/mg protein was approximately 10-fold higher than the level of geranylgeranyl 
group of protein; however, farnesol treatment did not modify cardiac cholesterol production. 
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In our present study, we have found that the cardiac tissue content of coenzyme Q9 
was comparable to that of protein-bound geranylgeranyl group. Cardiac level of coenzyme 
Q10 content was approximately 10-fold less than coenzyme Q9 or protein-bound 
geranylgeranyl group. Our result is in concordance with the findings of Matejíková et al. 
(2008) who reported that the rat heart contains approximately 10-fold more coenzyme Q9 
than coenzyme Q10 [97]. Coenzyme Q is a well-known antioxidant and cardioprotective 
molecule [44,98]. In our present study, farnesol treatment failed to alter coenzyme Q levels, 
which suggest that farnesol-induced cardioprotection is independent of changes in coenzyme 
Q levels. In our experiment the dolichol content of cardiac tissue did not change, but it was 
10-fold lower than protein-bound geranylgeranyl content. The role of dolichol in 
ischemia/reperfusion is not known in the literature. However, it was shown that dolichol 
kinase deficiency causes congenital dilated cardiomyopathy in patients [99,100]. 
Farnesol has been shown to exert antioxidant effect in vivo [36-38]. However, in our 
present study the cardioprotective dose of farnesol (1 mg/kg/day) failed to decrease 
peroxynitrite formation, a major player in oxidative/nitrosative stress. However, 
50 mg/kg/day farnesol, which did not show any cardioprotective effect, significantly 
decreased 3-nitrotyrosine a marker of peroxynitrite, demonstrating an antioxidant effect of 
farnesol. These results show that the cardioprotective effect of farnesol is independent from 
its antioxidant effect.  
We have found here that oral farnesol reduced infarct size in a U shaped dose-
dependent manner showing the maximum efficacy at 1 mg/kg/day
 
dose. Moreover, here we 
also demonstrated that farnesol exerts a similar concentration-dependent direct cytoprotective 
effect in cardiomyocytes in vitro. These results show that the cardioprotective effect of 
farnesol is not dependent on any systemic effect; however, it might be based on a direct 
cardiocytoprotective action. The reason for the inefficiency of higher farnesol doses (5 and 
50 mg/kg/day in in-vivo experiments and 2, 10, 50, 250 µM in neonatal rat cardiomyocyte 
experiments) has not been revealed in this study. However, one may speculate that the 
potential pro-apoptotic effect of farnesol may interfere with its cardioprotective effect at 
higher doses. Indeed, Chagas et al. (2009) found in a partial hepatectomy model that farnesol 
(250 mg/kg for 2 consecutive weeks) induced apoptosis in rat hepatocytes [101]. Joo et al. 
(2007) reported that 250 µM farnesol induced apoptosis in human lung carcinoma cell line 
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[102]. Indeed, we have found here that 250 µM farnesol radically decreased the viability of 
cardiomyocytes. 
The present study has clearly shown the cardioprotective effect of farnesol and 
revealed several aspect of its mechanism; however its cellular mechanism has not been fully 
explored. An obvious limitation of the present study is that total protein farnesylation and 
geranylgeranylation were measured and individual protein prenylation was not examined. 
Further studies are necessary to identify the specific geranylgeranylated proteins, which may 
play a role in the cardioprotective effect of farnesol.  
8.2 Study 2 
Our results show that dietary RPO supplementation reversed the negative effects of 
cholesterol supplementation in the ischemia/reperfusion rat heart model. Furthermore, dietary 
RPO supplementation reduced myocardial infarct size in cholesterol supplemented rats. 
Previous studies have shown that dietary RPO supplementation improved functional recovery 
of cholesterol fed rats after ischemia [56,58]. In the present study cholesterol supplementation 
was carried out for a longer period (nine weeks versus six weeks in previous studies). This 
indicates that RPO could effectively protect hearts against ischemia/reperfusion injury, 
despite a longer duration of cholesterol feeding. Osipov and co-workers (2009) found that 
hypercholesterolemic pigs had increased left ventricular function throughout the 
ischemia/reperfusion period when compared to normal pigs [17]. This was, however, 
associated with an increased infarct size and increased apoptotic markers. Our results together 
with previous studies [56,58] showed that dietary RPO can attenuate the harmful effects of 
cholesterol supplementation in the ischemia/reperfusion model. Our total serum cholesterol 
results were not increased in the cholesterol fed rats. This was expected, as a previous study 
employed a similar model of cholesterol feeding in rats, without achieving significant changes 
in serum cholesterol [103]. The effects of the cholesterol feeding on the cardiovascular system 
are however clearly discussed in the study of Giricz and coworkers (2003) through the 
depletion of nitric oxide, and our current study by increased myocardial infarct size [103]. 
Coronary flow in the Norm group was reduced by 70%, in the Chol group by 64%, in 
the Chol+RPO group by 57% and in the Norm+RPO group by 33% after ischemia. This 
indicates that RPO attenuated the fall in coronary flow after ischemia. This may suggest that 
RPO supplementation improves vascular function during reperfusion. 
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MMP2 activity was measured before ischemia in the cholesterol supplemented groups 
and compared to a Norm control group and a RPO supplemented group, as it may be expected 
that the cholesterol supplemented groups may have increased oxidative stress after 
supplementation. As increased oxidative stress leads to activation of MMP2 through redox 
modification of its regulatory subunit, this would be associated with changes in MMP2 
activity before ischemia which would be expected to be absent in normal rats [9,19,65-67]. 
Our results demonstrate for the first time that dietary RPO supplementation may alter 
myocardial oxidative stress before ischemia in cholesterol fed rats, as MMP2 activity was 
reduced before ischemia. The reduction in MMP2 activity before ischemia in rats 
supplemented with both cholesterol and RPO suggests that RPO was able to reduce oxidative 
stress in these rats. This would most probably be achieved through quenching of ROS, which 
is generated in greater proportions in cholesterol supplemented rats [14,103]. Increased 
generation of ROS and oxidative stress would normally be associated with activation of 
MMP2 [19,65,67]. As increased activity of MMP2 may lead to either cardiac remodeling, or 
tissue damage [61,71-73] , this reduction in MMP2 activity may play a role in RPO mediated 
protection against ischemia/reperfusion injury. However, MMP2 activity of the Norm +RPO 
was increased during reperfusion, when compared to normal rats without RPO 
supplementation. This would normally be associated with increased myocardial susceptibility 
to ischemia/reperfusion injury [62,74-77]. RPO was able to reduce myocardial infarct size in 
cholesterol fed rats, despite increased activity of MMP2 in reperfusion found in normal rats. 
This suggests MMP2 activity may only play a protective role in cholesterol fed rats, and that 
other protective pathways are responsible for RPO mediated protection in normal rats. 
The aim of this study was to investigate whether MMP2 activity was involved in RPO 
mediated protection of cholesterol fed rat hearts against ischemia/reperfusion. Our results 
suggest that MMP2 activity may play a role in RPO mediated protection of the hearts of the 
cholesterol fed rats, but not the hearts of SRC fed rats. This suggests that more pathways of 
protection may play a role in this protection. Kruger and co-workers (2007) found that RPO 
supplementation of cholesterol fed rats led to decreased phosphorylation of pro-apoptotic 
molecules, p38 and JNK [58]. This coincided with increased phosphorylation of the pro-
survival kinase ERK early in reperfusion, which leads to reduced apoptosis. Apoptosis has 
been shown to play a role in the detrimental effects of hypercholesterolemia in the heart. 
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Inhibition of apoptosis may therefore, explain the protective effects of RPO in this model 
[58].  
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Summary 
In conclusion, in the study 1, we have demonstrated that oral farnesol treatment 
reduces ischemia/reperfusion injury. Furthermore, we have shown that the cardioprotective 
effect of farnesol likely involves increased protein geranylgeranylation and seems to be 
independent of the other end-products of mevalonate pathway and the antioxidant effect of 
farnesol. 
In study 2 we showed that dietary RPO supplementation attenuated increased 
susceptibility of cholesterol fed rat hearts to ischemia/reperfusion injury as evidenced by 
reduced infarct size. Myocardial MMP2 activity was reduced in cholesterol and RPO 
supplemented rat hearts before ischemia (Figure 10), but not after ischemia (Figure 11) 
associated with decreased infarct size. This may suggest a different or additional mechanism 
of protection. 
Acute myocardial infarction is currently the leading causes of morbidity and mortality 
in the world. Myocardial infarction has several risk factors and these risk factors likely lead 
finally to cardiovascular events. Rapid reclamation of blood flow to the ischemic zone can 
decrease the mortality of myocardial infarction but it is still high. Therefore, the prevention of 
myocardial infarction is foremost goal. Here we presented oral pretreatments with two widely 
used natural food additives which decrease ischemia/reperfusion injury. It may improve the 
compliance of patients (with risk factors) and increase the effectiveness of prevention of 
ischemic heart diseases that these materials are natural and orally usable. However, further 
investigations are needed to understand the mechanism of protective effect of farnesol and 
RPO. Further understanding of the biochemical mechanism of the protective effect of farnesol 
and RPO may help to develop new and more effective prevention of acute myocardial 
infarction.  
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